5-bromo-2-iodobenzo[d]thiazole | 1175278-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 5-bromo-2-iodobenzo[d]thiazole
• 英文别名: 5-bromo-2-iodo-1,3-benzothiazole
• CAS: 1175278-25-7
• 化学式: C₇H₃BrINS
• 分子量: 339.982
• InChiKey: HFKFVSKHOWYRQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-2-iodobenzo[d]thiazole 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 13.0h， 生成 N-((S)-1'-(2-(2,3-dichlorophenyl)benzo[d]thiazol-5-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-yl)-2-methylpropane-2-sulfinamide
  参考文献：
  名称：

  含氮杂环化合物及其制备方法和应用

  摘要：

  本发明公开了一种含氮杂环化合物及其制备方法和应用。具体地，本发明公开了一种式I所示化合物或其药学上可接受的盐。本发明的化合物具有较好的SHP2抑制活性和/或肿瘤细胞抑制活性。#imgabs0#

  公开号：

  CN116731038A
• 作为产物：
  描述：

  5-溴苯并噻唑 在 全氟碘代丁烷 、 sodium t-butanolate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以90 %的产率得到5-bromo-2-iodobenzo[d]thiazole
  参考文献：
  名称：

  含氮杂环化合物及其制备方法和应用

  摘要：

  本发明公开了一种含氮杂环化合物及其制备方法和应用。具体地，本发明公开了一种式I所示化合物或其药学上可接受的盐。本发明的化合物具有较好的SHP2抑制活性和/或肿瘤细胞抑制活性。#imgabs0#

  公开号：

  CN116731038A

文献信息

• 2-AMINOPYRIDINE KINASE INHIBITORS
  申请人：Steinig Arno G.

  公开号：US20090197862A1

  公开（公告）日：2009-08-06

  2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

  具有Formula I结构的2-氨基吡啶化合物，以及这些化合物的药用可接受的盐。Formula I的化合物抑制动物（包括人类）中的酪氨酸激酶酶活性，并可用于治疗和/或预防各种疾病和病况。特别地，本文披露的化合物是激酶抑制剂，特别是但不限于KDR、Tie-2、Flt3、FGFR3、Ab1、Aurora A、c-Src、IGF-1R、ALK、c-MET、RON、PAK1、PAK2和TAK1，并可用于治疗增生性疾病，如但不限于癌症。本发明还涉及一种包含Formula I化合物的药物组合物，或其药用可接受的盐，以及药用可接受的载体的药物组合物。本发明还涉及一种通过向患有由蛋白激酶活性介导的病症的患者投与上述药物组合物的治疗方法。
• 2-aminopyridine kinase inhibitors
  申请人：OSI Pharmaceuticals, LLC

  公开号：US08178668B2

  公开（公告）日：2012-05-15

  2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

  具有I式结构的2-氨基吡啶化合物，以及这些化合物的药学上可接受的盐。I式化合物抑制动物（包括人类）中的酪氨酸激酶酶活性，并在治疗和/或预防各种疾病和病况方面有用。特别地，本文披露的化合物是激酶抑制剂，特别是但不限于KDR，Tie-2，Flt3，FGFR3，Ab1，Aurora A，c-Src，IGF-1R，ALK，c-MET，RON，PAK1，PAK2和TAK1，并可用于治疗增殖性疾病，例如但不限于癌症。本发明还涉及一种制备药物组合物的方法，该组合物包括I式化合物或其药学上可接受的盐的治疗有效量以及药学上可接受的载体。本发明还涉及一种通过向患有蛋白激酶活性介导的病症的患者投与上述药物组合物的治疗方法。
• Copper‐Catalyzed Aryne Insertion into the Carbon‐Iodine Bond of Heteroaryl Iodides
  作者：Wen‐Xuan Cao、Lei Zhu、Yiyi He、Run Wang、Ming Liu、Qin Ouyang、Qing Xiao

  DOI：10.1002/anie.202305146

  日期：2023.9.25

  Aryne insertions into the carbon‐iodine bond of heteroaryl iodides has been achieved for the first time. This novel reaction provides an efficient pathway for the synthesis of valuable building blocks 2‐iodoheterobiaryls from heteroaryl iodides and o‐silylaryl triflates in excellent regioselectivity. The copper(I) catalyst, which bears a N‐heterocyclic carbene (NHC) ligand, is essential to accomplish the reaction. Control reactions and DFT calculations indicate that the coordination of copper, as a Lewis acid, with nitrogen atoms of heteroaryl iodides mediates the insertion of arynes into heteroaryl carbon‐iodine bonds.

  摘要 首次实现了在杂芳基碘化物的碳-碘键中插入丙烯。这一新型反应为从杂芳基碘化物和邻硅芳基三酸酯合成有价值的 2-iodoheterobiaryls 构建模块提供了一条高效途径，且具有极佳的区域选择性。铜（I）催化剂带有 N-杂环碳烯（NHC）配体，对完成反应至关重要。对照反应和 DFT 计算表明，作为路易斯酸的铜与杂芳基碘化物的氮原子配位介导了芳基插入杂芳基碳-碘键。
• US8178668B2
  申请人：——

  公开号：US8178668B2

  公开（公告）日：2012-05-15
• [EN] 2-AMINOPYRIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE 2-AMINOPYRIDINE KINASES
  申请人：OSI PHARM INC

  公开号：WO2009099982A1

  公开（公告）日：2009-08-13

  2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, F1t3, FGFR3, Ab1, Aurora A, c-Src, IGF- IR, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.